Supernus Pharmaceuticals (SUPN) Cash from Investing Activities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Investing Activities data on file, last reported at -$19.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$19.2 million, down 151.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$52.4 million (up 48.05% YoY), and the FY2025 annual result was $4.1 million, up 102.16% from the prior year.
• Cash from Investing Activities rose to -$19.2 million in Q1 2026 per SUPN's latest filing, from -$51.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $239.8 million in Q1 2023 and troughed at -$82.2 million in Q3 2022.
• A 5-year average of -$9.0 million and a median of -$30.6 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 1341.65% in 2022, then surged 484.57% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$48.8 million in 2022, then sank by 35.3% to -$66.0 million in 2023, then soared by 80.85% to -$12.6 million in 2024, then tumbled by 306.0% to -$51.3 million in 2025, then soared by 62.55% to -$19.2 million in 2026.
• Business Quant data shows SUPN's Cash from Investing Activities at -$19.2 million in Q1 2026, -$51.3 million in Q4 2025, and $48.7 million in Q3 2025.